ACS Applied Materials & Interfaces · 2021 · 55 citations · 36 references
Life SciencesNeurosciencePharmacologyDrug DesignNanomaterialsProtein-protein InteractionsAlzheimer DiseaseAmyloid FormationNanomedicineNanoparticle DesignProtein AggregationProtein Aggregation DisordersAmyloid Beta AggregationAmyloid Beta-targeted TherapyNeurotoxicityPolymeric MicellesTau AggregationTau Protein AggregationTau SeedingTau-targeted Therapy
With the failure of various amyloid-β-targeted drugs for Alzheimer's disease (AD) in clinical trials, tau protein has gained growing attention as an alternative therapeutic target in recent years. The aggregation of tau exerts neurotoxicity, and its spreading in the brain is associated with increasing severity of clinical symptoms for AD patients; thus tau-targeting therapies hold great potential against AD. Here, a tau-targeted multifunctional nanoinhibitor based on self-assembled polymeric micelles decorated with tau-binding peptide is devised for AD treatment. Through the multivalent binding effect with the aggregating protein, this nanoinhibitor is capable of efficiently inhibiting tau protein aggregation, recognizing tau aggregates, and blocking their seeding in neural cells, thus remarkably mitigating tau-mediated cytotoxicity. Moreover, the formed nanoinhibitor-tau complex after binding is more easily degraded than mature tau aggregates, which will be conducive to enhance the therapeutic effect. We believe that this multifunctional nanoinhibitor will promote the development of new antitau strategies for AD treatment.
36
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois, Howard Feldman, Claudia Jacova et al. · The Lancet Neurology · 2014 · 3.3K citations · Full text
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody, Rema Raman, Martin R. Farlow et al. · New England Journal of Medicine · 2013 · 1.2K citations